ClinicalTrials.gg
TerminatedNCT00157261Updated Oct 29, 2013

Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial

A Phase 3 interventional study of tenecteplase in Heart Arrest, sponsored by Boehringer Ingelheim. Terminated at 68 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-29.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,050
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Heart Arrest with a site in Germany — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Germany.

Enrollment
3rd of 23
1,050 · median 150
Started
2004
with 1 other
Phase 3
Only one
of the 38
Registered
1st of 38
by date
Lead sponsor
1 of 38
Boehringer Ingelheim

Among the 38 studies in Heart Arrest with a site in Germany, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2004, is the only one in phase 3, and was the 1st registered.

Heart Arrest

926 studies on the registry are indexed under Heart Arrest; 226 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

8 of the 38 studies in Heart Arrest with a site in Germany are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Heart Arrest with a site in Germany, or all of them as a file.
02

Study summary

The general aim of this study is to compare the efficacy and safety of tenecteplase to standard treatment during cardiopulmonary resuscitation in patients suffering from out-of-hospital cardiac arrest.

Read the detailed description

The trial is a prospective, international, multi-centre, randomised (1:1), double-blind, parallel group comparison conducted for investigating the efficacy and safety of tenecteplase and placebo in patients with cardiac arrest of presumed cardiac origin.

Approximately 1300 patients (two groups of 650 patients; tenecteplase or matching placebo) suffering from witnessed (by eye or ear) out-of-hospital cardiac arrest of presumed cardiac origin, who are treated with ALS-CPR will be randomised at approximately 40 study centres. Randomisation is done immediately after insertion of an IV line is established. Study drug application, as a single IV bolus over 5-10 seconds, should be done immediately after the first vasopressor application during the ALS-CPR procedure.

PCI facilities will be required at all participating sites, i.e. hospitals receiving patients.

Study Hypothesis:

The primary aim of the trial is to demonstrate superiority in the intent-to-treat analysis of tenecteplase over placebo with regard to primary endpoint as the incidence of 30-day survival (30daysurv).

Comparison(s):

Group A (experimental; fibrinolytic treatment) Tenecteplase, as a single IV bolus over 5-10 seconds, immediately after first vasopressor dosage during standardised ALS-CPR procedures according to the International CPR Guidelines.

Group B (reference) Placebo, as a single IV bolus over 5-10 seconds, immediately after first vasopressor dosage during standardised ALS-CPR procedures according to the International CPR Guidelines.

03

Conditions studied

  • Heart Arrest

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Patients, indicated for pre-hospital ALS-CPR procedures* must fulfil the following inclusion criteria:

  • Age at least 18 years (known or estimated; no upper limit)
  • Out-of-hospital cardiac arrest of presumed cardiac origin (including recurrent cardiac arrest(s) after initial ROSC)
  • Witnessed (by eye and/or ear) cardiac arrest
  • BLS-CPR started within 10 min of onset (known or estimated time) and may be performed for up to 10 min, followed by ALS-CPR - or ALS-CPR started within 10 min of onset (known or estimated time)

Subjects who meet any of the following criteria will be excluded from randomisation into the study:

  • In-hospital cardiac arrest
  • Cardiac arrest of presumed non-cardiac origin (e.g., drug overdose, carbon monoxide poisoning, drowning, hypothermia, exsanguination, electrocution, asphyxia, hypoxia, trauma, cerebrovascular accident)
  • Obvious significant internal bleeding
  • Known neurological impairment
  • Known coagulation disorder
  • Known pregnancy
  • Known current participation in any other clinical study
  • Known to study medication
  • Institutionalised subjects (e.g., prisoner)
  • Any other condition that the investigator feels would place the patient at increased risk if the therapy is initiated
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,050 participants

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint of this study is the 30-day survival rate

    Time frame: 30 days

  2. The co-primary endpoint of this study is hospital admission

    Time frame: 30 days

Secondary outcomes

  1. Return of spontaneous circulation (ROSC)

    Time frame: 30 days

  2. 24-hr survival

    Time frame: 24 hours

  3. Neurological and overall outcome at hospital discharge or at day 30, whichever came first

    Time frame: 30 days

  4. Symptomatic intracranial haemorrhage (ICH) up to hospital discharge or day 30, whichever came first

    Time frame: 30 days

  5. Major bleeds up to hospital discharge or day 30, whichever came first

    Time frame: 30 days

07

Study locations

68 sites
  • Univ.-Klinik f. Anaesthesie Graz
    Graz, 8036, Austria
  • Univ.-Klinik f. Anaesthesie u. Intensivmedizin
    Innsbruck, 6020, Austria
  • LKH Salzburg, St. Johanns-Spital
    Salzburg, 5020, Austria
  • Univ.-Klinik f. Notfallmedizin
    Wien, 1090, Austria
  • Algemeen Ziekenhuis Antwerpen / Campus Stuivenberg
    Antwerpen, 2060, Belgium
  • AZ Sint-Jan AV
    Brugge, 8000, Belgium
  • CHU Saint-Pierre
    Bruxelles, 1000, Belgium
  • AZ VUB
    Bruxelles, 1090, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • AZ Groeningen
    Kortrijk, 8500, Belgium
  • CHU de Tivoli
    La Louvière, 7100, Belgium
  • Universitaire Ziekenhuizen Leuven
    Leuven, 3000, Belgium
  • CHR de la Citadelle
    Liège, 4000, Belgium
  • CHR de Namur
    Namur, 5000, Belgium
  • Hôpital Jean Minjoz
    Besançon cedex, 25030, France
  • Hôpital Avicenne
    Bobigny cedex, 93009, France
  • Hôpital Henri Mondor
    Creteil cedex, 94010, France
  • Hôpital André Mignot
    Le Chesnay, 78150, France
  • Hôpital Régional et Universitaire
    Lille cedex, 59037, France
  • Hôpital Marc Jacquet
    Melun cedex, 77011, France
  • Hôpital Lapeyronie
    Montpellier cedex 5, 34295, France
  • Hôpital Necker
    Paris cedex 15, 75743, France
  • Hôpital Charles Nicolle
    Rouen cedex, 76031, France
  • Hôpital Purpan
    Toulouse cedex, 31059, France
  • Hôpital Pierre Bazin
    Voiron cedex, 38506, France
  • Universitätsklinikum Benjamin Franklin
    Berlin, 12200, Germany
  • Humboldt-Klinikum
    Berlin, 13504, Germany
  • DRK Kliniken Westend
    Berlin, 14050, Germany
  • Städtische Kliniken Bielefeld gem. GmbH
    Bielefeld, 33604, Germany
  • Klinikum der Ruhr-Universität Bochum
    Bochum, 44791, Germany
  • Knappschaftskrankenhaus Dortmund
    Dortmund, 44309, Germany
  • Chirurgische Universität Freiburg
    Freiburg/Breisgau, 79106, Germany
  • Georg-August Universität Göttingen
    Göttingen, 37075, Germany
  • Martin-Luther-Universität Halle
    Halle/Saale, 06120, Germany
  • Universität Heidelberg
    Heidelberg, 69120, Germany
  • Friedrich-Schiller Universität Jena
    Jena, 07740, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Berufsfeuerwehr Kiel
    Kiel, 24116, Germany
  • Universitätsklinikum Mannheim
    Mannheim, 68168, Germany
  • Klinikum rechts der Isar
    München, 81675, Germany
  • Klinikum Saarbrücken gGmbH
    Saarbrücken, 66119, Germany
  • Universitätsklinikum Ulm
    Ulm, 89075, Germany
  • A. O. Ospedali Riuniti di Bergamo
    Bergamo, 24100, Italy
  • Ospedale S. Anna
    Como, 22100, Italy
  • A. O. Universitaria S. Martino
    Genova, 16132, Italy
  • A. O. San Gerardo di Monza
    Monza, 20052, Italy
  • Policlinico S. Matteo
    Pavia, 27100, Italy
  • Osp. di Circolo Fondazione Macchi
    Varese, 21100, Italy
  • ICU, Haukeland Universitetssykehus
    Bergen, N-5021, Norway
  • ICU, Sykehuset Østfold Fredrikstad
    Fredrikstad, N-1603, Norway
  • Akuttklinikken / NLA, Sentralsjukehuset i Rogaland
    Stavanger, N-4068, Norway
  • Pre Hospital Klinikk, Sykehuset i Vestfold Tønsberg
    Tønsberg, N-3101, Norway
  • Hospital de Torrecárdenas / ICU
    Almería, 04009, Spain
  • Hospital Clínico Provincial de BCN / Cardiology Service
    Barcelona, 08036, Spain
  • Hospital Universitario Reina Sofía / ICU
    Cordoba, 14004, Spain
  • Vírgen de las Nieves. Critical Care-Emergency Room
    Granada, 18012, Spain
  • Hospital de Jerez de la Frontera / ICU
    Jerez de la Frontera, 11407, Spain
  • Hospital Clínico San Carlos / Hemodynamics
    Madrid, 28040, Spain
  • Hospital Clínico Universitario Vírgen de la Victoria / ICU
    Malaga, 29010, Spain
  • Boehringer Ingelheim Investigational Site
    Sevilla, 41014, Spain
  • Complejo Hospitalario Universitario de Vigo / Cardiology
    Vigo, 36214, Spain
  • Hospital Clinico Univ. Lozano Blesa
    Zaragoza, 50009, Spain
  • Anestesikliniken
    Gävle, 807 87, Sweden
  • Hjärt/Kärlforskn.enheten, Sahlgrenska Univ.sjh. Göteborg
    Göteborg, 413 45, Sweden
  • Södersjukhuset
    Stockholm, 118 83, Sweden
  • Universitetssjukhuset
    Örebro, 701 85, Sweden
  • Centre interdisciplinaire des urgences (CIU), CHUV BH 06-429
    Lausanne, 1005, Switzerland
  • Boehringer Ingelheim Investigational Site
    Lugano, 6900, Switzerland
08

References and documents

Publications

  • Bottiger BW, Arntz HR, Chamberlain DA, Bluhmki E, Belmans A, Danays T, Carli PA, Adgey JA, Bode C, Wenzel V; TROICA Trial Investigators; European Resuscitation Council Study Group. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008 Dec 18;359(25):2651-62. doi: 10.1056/NEJMoa070570. PubMed 19092151 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2004, a primary completion of Jun 2006 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
Start
Jan 2004
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Oct 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Oct 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00157261
First posted
Sep 12, 2005
Start date
Jan 2004
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Oct 29, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · B.I. Pharma GmbH & Co. KG
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenecteplase

Start the discussion